{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:37:46Z","timestamp":1783427866582,"version":"3.54.6"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common form of dementia. Mutations in genes and precursors of <jats:italic>\u03b2<\/jats:italic> amyloid (A\u03b2) are found in the familial form of the disease. This led to the evaluation of seven monoclonal antibodies against A\u03b2 in subjects with AD, two of which were approved for use by the FDA. They caused only a small improvement in cognitive function, probably because they were given to those with much more prevalent sporadic forms of dementia. They also have potentially serious adverse effects. Oxidative stress and elevated pro-inflammatory cytokines are present in all subjects with AD and are well correlated with the degree of memory impairment. Drugs that affect these processes include TNF\u03b1 blocking antibodies and MAPK p38 inhibitors that reduce cognitive impairment when given for other inflammatory conditions. However, their adverse effects and inability to penetrate the brain preclude their use for dementia. Rosiglitazone is used to treat diabetes, a risk factor for AD, but failed in a clinical trial because it was given to subjects that already had dementia. Ladostigil reduces oxidative stress and suppresses the release of pro-inflammatory cytokines from activated microglia without blocking their effects. Chronic oral administration to aging rats prevented the decline in memory and suppressed overexpression of genes adversely affecting synaptic function in relevant brain regions. In a phase 2 trial, ladostigil reduced the decline in short-term memory and in whole brain and hippocampal volumes in human subjects with mild cognitive impairment and had no more adverse effects than placebo.<\/jats:p>","DOI":"10.3389\/fnagi.2024.1484615","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:29:19Z","timestamp":1733725759000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic agents for Alzheimer\u2019s disease: a critical appraisal"],"prefix":"10.3389","volume":"16","author":[{"given":"Marta","family":"Weinstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fnmol.2015.00021","article-title":"The role of the ubiquitin-editing enzyme A20 in diseases of the central nervous system and other pathological processes","volume":"8","author":"Abbasi","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1533317519899546","DOI":"10.1177\/1533317519899546","article-title":"Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS","volume":"35","author":"Akimoto","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J. Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","article-title":"Alzheimer's disease neuroimaging initiative investigators. Sex modifies the APOE-related risk of developing Alzheimer disease","volume":"75","author":"Altmann","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and Meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/NEN.0b013e3181cb5af4","article-title":"Oxidative stress in the progression of Alzheimer disease in the frontal cortex","volume":"69","author":"Ansari","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/156720512801322573","article-title":"Overview and findings from the religious orders study","volume":"9","author":"Bennett","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"CD001190","DOI":"10.1002\/14651858","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/ijms24010884","article-title":"Microglial activation and priming in Alzheimer's disease: state of the art and future perspectives","volume":"24","author":"Bivona","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"879021","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 Inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1158\/1055-9965.EPI-12-0495","article-title":"Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer","volume":"21","author":"Breyer","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/156720507781077313","article-title":"Executive Dyscontrol in dementia, with emphasis on subcortical pathology and the role of Butyrylcholinesterase","volume":"4","author":"Bullock","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.freeradbiomed.2021.10.036","article-title":"Ubiquitin carboxyl-terminal hydrolase L-1 in brain: focus on its oxidative\/nitrosative modification and role in brains of subjects with Alzheimer disease and mild cognitive impairment","volume":"177","author":"Butterfield","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3233\/JAD-160726","article-title":"Mitochondrial aspects of synaptic dysfunction in Alzheimer's disease","volume":"57","author":"Cai","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/art.24266","article-title":"Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis","volume":"60","author":"Cohen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/0165-6147(90)90011-V","article-title":"Excitatory amino acid receptors and synaptic plasticity","volume":"11","author":"Collingridge","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jacc.2019.10.062","article-title":"Alzheimer's disease and vascular aging: JACC focus seminar","volume":"75","author":"Cortes-Canteli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2322.e19","DOI":"10.1016\/j.neurobiolaging.2010.05.023","article-title":"Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification","volume":"32","author":"Davatzikos","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer's disease","volume":"88","author":"de la Monte","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1568009622666220215142837","article-title":"Inhibitors and activators of the p38 mitogen-activated MAP kinase (MAPK) family as drugs to treat Cancer and inflammation","volume":"22","author":"Denny","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of Verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/610813","article-title":"Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF","volume":"2015","author":"Fischer","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/glia.21071","article-title":"The P2X7-Egr pathway regulates nucleotide-dependent inflammatory gene expression in microglia","volume":"59","author":"Friedle","year":"2011","journal-title":"Glia"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13195-020-00617-2","article-title":"A selective p38alpha\/beta MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse","volume":"12","author":"Gee","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10637-017-0532-2","article-title":"Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer","volume":"36","author":"Goldman","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s10072-018-3507-y","article-title":"Free and cued selective reminding test predicts progression to Alzheimer's disease in people with mild cognitive impairment","volume":"39","author":"Grande","year":"2018","journal-title":"Neurol. Sci."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3233\/JAD-2009-0976","article-title":"Inflammation and NF-kappaB in Alzheimer's disease and diabetes","volume":"16","author":"Granic","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1189\/jlb.72.2.233","article-title":"Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer\u2019s disease","volume":"72","author":"Griffin","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10522-015-9618-4","article-title":"Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease","volume":"17","author":"Grimm","year":"2016","journal-title":"Biogerontology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extra-synaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1185\/03007995.2014.939167","article-title":"Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings","volume":"30","author":"Henley","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1046\/j.1471-4159.1999.0722053.x","article-title":"p38 kinase is activated in the Alzheimer's disease brain","volume":"72","author":"Hensley","year":"1999","journal-title":"J. Neurochem."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","article-title":"The discovery of Alzheimer's disease","volume":"5","author":"Hippius","year":"2003","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"643254","DOI":"10.3389\/fphar.2021.643254","article-title":"Neurodegenerative disease and the NLRP3 Inflammasome","volume":"12","author":"Holbrook","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neurobiolaging.2017.12.018","article-title":"Amyloid pathology in the progression to mild cognitive impairment","volume":"64","author":"Insel","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","article-title":"Imaging the evolution and pathophysiology of Alzheimer disease","volume":"19","author":"Jagust","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"19453","DOI":"10.1074\/jbc.M301938200","article-title":"Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus","volume":"278","author":"Kelly","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.drudis.2016.08.001.S1359-6446(16)30288-4","article-title":"Neuroinflammation induces neurodegeneration","volume":"1","author":"Kempuraj","year":"2016","journal-title":"J. Neurol. Neurosurg. Spine"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1515\/revneuro-2018-0008","article-title":"Role of p38\/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy","volume":"30","author":"Kheiri","year":"2018","journal-title":"Rev. Neurosci."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.cccb.2023.100158","article-title":"Fornix degeneration in risk factors of Alzheimer's disease, possible trigger of cognitive decline","volume":"4","author":"Lacalle-Aurioles","year":"2023","journal-title":"Cereb. Circ. Cogn. Behav."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1002\/dmrr.252","article-title":"Differentiating members of the thiazolidinedione class: a focus on safety","volume":"18","author":"Lebovitz","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/molecules22081287","article-title":"Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease","volume":"22","author":"Lee","year":"2017","journal-title":"Molecules"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"937486","DOI":"10.3389\/fnagi.2022.937486","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019","volume":"14","author":"Li","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"108229","DOI":"10.1016\/j.neuropharm.2020.108229","article-title":"Effect of ladostigil treatment of aging rats on gene expression in four brain areas associated with regulation of memory","volume":"177","author":"Linial","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"n3127","DOI":"10.1136\/bmj.n3127","article-title":"Aducanumab: European agency rejects Alzheimer\u2019s drug over efficacy and safety concerns","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"o2912","DOI":"10.1136\/bmj.o2912","article-title":"Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain","volume":"379","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00109-016-1427-y","article-title":"Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders","volume":"94","author":"Mahley","year":"2016","journal-title":"J. Mol. Med. (Berl)"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"103914","DOI":"10.1016\/j.cellimm.2019.04.002","article-title":"A20: a multifunctional tool for regulating immunity and preventing disease","volume":"340","author":"Malynn","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.yjmcc.2010.10.021","article-title":"The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure","volume":"51","author":"Marber","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s0304-3940(03)00211-8","article-title":"Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor","volume":"341","author":"Maruyama","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e0123289","DOI":"10.1371\/journal.pone.0123289","article-title":"Memantine monotherapy for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"10","author":"Matsunaga","year":"2015","journal-title":"PLoS One"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"CD003154","DOI":"10.1002\/14651858.CD003154.pub6","article-title":"Memantine for dementia","volume":"3","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1210\/jc.2003-032103","article-title":"Evidence for a potent anti-inflammatory effect of rosiglitazone","volume":"89","author":"Mohanty","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/d41573-019-00064-1","article-title":"Anti-amyloid failures stack up as Alzheimer antibody flops","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMe078117","article-title":"Rosiglitazone and cardiotoxicity--weighing the evidence","volume":"357","author":"Nathan","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11481-012-9358-z","article-title":"Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells","volume":"7","author":"Panarsky","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cells8111383","article-title":"The role of signaling pathways of inflammation and oxidative stress in development of senescence and aging phenotypes in cardiovascular disease","volume":"8","author":"Papaconstantinou","year":"2019","journal-title":"Cells"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejphar.2008.06.016","article-title":"Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats","volume":"589","author":"Pathan","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3233\/JAD-160275","article-title":"Pharmacological agents targeting gamma-secretase increase risk of Cancer and cognitive decline in Alzheimer's disease patients: a systematic review and Meta-analysis","volume":"53","author":"Penninkilampi","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J. Intern. Med."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-021-00843-2","article-title":"A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease","volume":"13","author":"Prins","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/biom14010112","article-title":"Ladostigil reduces the Adenoside triphosphate\/lipopolysaccharide-induced secretion of pro-inflammatory cytokines from microglia and modulate-immune regulators, TNFAIP3, and EGR1","volume":"14","author":"Reichert","year":"2024","journal-title":"Biomol. Ther."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12031-014-0398-0","article-title":"P38 MAPK inhibition protects against glutamate neurotoxicity and modifies NMDA and AMPA receptor subunit expression","volume":"55","author":"Rivera-Cervantes","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1212\/WNL.0b013e318245d295","article-title":"beta-amyloid burden in healthy aging: regional distribution and cognitive consequences","volume":"78","author":"Rodrigue","year":"2012","journal-title":"Neurology"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1567205019666220127102640","article-title":"Role of inflammatory cytokines in the conversion of mild cognitive impairment to dementia: a prospective study","volume":"19","author":"Romero-Sevilla","year":"2022","journal-title":"Curr. Alzheimer Res."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e1474","DOI":"10.1212\/WNL.0000000000008239","article-title":"Low-dose ladostigil for mild cognitive impairment: a phase 2 placebo-controlled clinical trial","volume":"93","author":"Schneider","year":"2019","journal-title":"Neurology"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11481-018-9817-2","article-title":"Age-induced spatial memory deficits in rats are correlated with specific brain region alterations in microglial morphology and gene expression","volume":"14","author":"Shoham","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1439760","article-title":"Production of the Alzheimer amyloid beta protein by normal proteolytic processing","volume":"258","author":"Shoji","year":"1992","journal-title":"Science"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainresbull.2011.10.004","article-title":"Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases","volume":"87","author":"Smith","year":"2012","journal-title":"Brain Res. Bull."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2165\/00002512-199813050-00005","article-title":"Rivastigmine. Review of its use in Alzheimer\u2019s disease","volume":"13","author":"Spencer","year":"1998","journal-title":"Drugs Aging"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1021\/jm020120c","article-title":"Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease","volume":"45","author":"Sterling","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref88","first-page":"25","article-title":"TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study","volume":"8","author":"Tobinick","year":"2006","journal-title":"Med. Gen. Med."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JAD-200711","article-title":"Therapeutic potential of TNF-\u03b1 inhibition for Alzheimer\u2019s disease prevention","volume":"78","author":"Torres-Acosta","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1155\/2015\/105828","article-title":"Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer\u2019s disease","volume":"2015","author":"Verdile","year":"2015","journal-title":"Mediators Inflamm"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41467-018-04376-5","article-title":"A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation","volume":"9","author":"Voet","year":"2018","journal-title":"Nat. Commun."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer\u2019s disease","volume":"271","author":"Watkins","year":"1994","journal-title":"JAMA"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S2213-2600(13)70200-5","article-title":"Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Watz","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11481-013-9433-0","article-title":"Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats","volume":"8","author":"Weinstock","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<216::AID-DDR4>3.0.CO;2-Z","article-title":"Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer\u2019s disease, with cholinesterase and monoamine oxidase inhibitory activities","volume":"50","author":"Weinstock","year":"2000","journal-title":"Drug Dev. Res."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cbi.2008.03.014","article-title":"Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity","volume":"175","author":"Weinstock","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.brainres.2008.09.074","article-title":"PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms","volume":"1244","author":"Yi","year":"2008","journal-title":"Brain Res."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3892\/etm.2021.10175","article-title":"Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-\u03baB and in a PPAR\u03b3-dependent manner","volume":"22","author":"Zhou","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1046\/j.1471-4159.2001.00597.x","article-title":"Activation of MKK6, an upstream activator of p38, in Alzheimer's disease","volume":"79","author":"Zhu","year":"2001","journal-title":"J. Neurochem."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1484615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:29:23Z","timestamp":1733725763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1484615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":102,"alternative-id":["10.3389\/fnagi.2024.1484615"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2024.1484615","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"article-number":"1484615"}}